Zinc Acetate/Carrageenan Gels Exhibit Potent Activity In Vivo against High-Dose Herpes Simplex Virus 2 Vaginal and Rectal Challenge
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Topical microbicides that block the sexual transmission of HIV and herpes simplex virus 2 (HSV-2) are desperately needed to reduce the incidence of HIV infections worldwide. Previously we completed phase 3 testing of the carrageenan-based gel Carraguard. Although the trial did not show that Carraguard is effective in preventing HIV transmission during vaginal sex, it did show that Carraguard is safe when used weekly for up to 2 years. Moreover, Carraguard has in vitro activity against human papillomavirus (HPV) and HSV-2 and favorable physical and rheological properties, which makes it a useful vehicle to deliver antiviral agents such as zinc acetate. To that end, we previously reported that a prototype zinc acetate carrageenan gel protects macaques against vaginal challenge with combined simian-human immunodeficiency virus reverse transcriptase (SHIV-RT). Herein, we report the safety and efficacy of a series of zinc acetate and/or carrageenan gels. The gels protected mice (75 to 85% survival; P < 0.001) against high-dose (10 6 -PFU) HSV-2 vaginal or rectal challenge. In contrast, zinc acetate formulated in HEC (hydroxyethylcellulose; or the Universal Placebo) failed to protect mice against the high-dose vaginal HSV-2 challenge (similar to aqueous zinc acetate solution and the placebo controls). The gels were found to be effective spreading gels, exhibited limited toxicity in vitro , caused minimal damage to the architecture of the cervicovaginal and rectal mucosae in vivo , and induced no increased susceptibility to HSV-2 infection in a mouse model. Our results provide a strong rationale to further optimize and evaluate the zinc acetate/carrageenan gels for their ability to block the sexual transmission of HIV and HSV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.10 · Cited by 5,163
Abdool Karim, Q., Abdool Karim, S. S., Frohlich, J. A., Grobler, A. C., Baxter, C., Mansoor, L. E., Kharsany, A. B. M., Sibeko, S., Mlisana, K. P., Omar, Z., et al. (2010) · Science · doi:10.1126/science.1193748 · Cited by 2,435
Freeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A., & Hayes, R. J. (2006) · AIDS · doi:10.1097/01.aids.0000198081.09337.a7 · Cited by 1,192
Skoler-Karpoff, S., Ramjee, G., Ahmed, K., Altini, L., Plagianos, M. G., Friedland, B., Govender, S., De Kock, A., Cassim, N., Palanee, T., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61842-5 · Cited by 502 · cited 1×
“This favorable safety profile, as well as good physical/rheological properties, makes carrageenan-based gels a potentially useful vehicle for future microbicides (12, 13, 15, 25, 26, 35, 37, 44, 49, 50).”
BackgroundPrasad, A. S., Beck, F. W. J., Bao, B., Snell, D., & Fitzgerald, J. T. (2008) · The Journal of Infectious Diseases · doi:10.1086/528803 · Cited by 121
Cited by
Zinc Therapy in Dermatology: A Review
Gupta, M., Mahajan, V. K., Mehta, K. S., & Chauhan, P. S. (2014) · Dermatology Research and Practice · doi:10.1155/2014/709152 · Cited by 300
“In vivo use of zinc acetate gel has been found effective in preventing sexual transmission ofHSV-2 andHIV infections [17].”
BackgroundChen, M. X., Alexander, K. S., & Baki, G. (2016) · Journal of Pharmaceutics · doi:10.1155/2016/5754349 · Cited by 173
Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection
Steinbach, J. M., Weller, C. E., Booth, C. J., & Saltzman, W. M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.008 · Cited by 113
Metadata
- Authors
- Fernández-Romero, J. A., Abraham, C. J., Rodriguez, A., Kizima, L., Jean-Pierre, N., Menon, R., Begay, O., Seidor, S., Ford, B. E., Gil, P. I., Peters, J., Katz, D., Robbiani, M., & Zydowsky, T. M.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2012-01
- Volume
- 56
- Issue
- 1
- Pages
- 358-368
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2150417136
- Cited by
- 70
- References
- 5
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.